Tiburio Therapeutics is a biopharmaceutical company, which is dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases. The Company's pipeline consists of two clinical stage compounds: TBR-760 for the treatment of non-functioning pituitary adenoma, and TBR-065 for additional rare endocrine diseases.
Type | Private | |
Founded | 2018 | |
HQ | Cambridge, MA, US | Map |
Website | tiburio.com |
Employees (est.) (Apr 2021) | 7 | (-22%) |
Cybersecurity rating | A | More |
Founding Date | 2018 |
Tiburio Therapeutics total Funding | $31 m |
Tiburio Therapeutics latest funding size | $31 m |
Time since last funding | 3 years ago |
Tiburio Therapeutics investors | New Enterprise Associates, Longitude Capital, Alexandria Venture Investments, Lundbeckfonden Ventures |
Tiburio Therapeutics has 91 Twitter Followers. The number of followers has decreased 1.4% quarter over quarter
When was Tiburio Therapeutics founded?
Tiburio Therapeutics was founded in 2018.
Who are Tiburio Therapeutics key executives?
Tiburio Therapeutics's key executives are Chris Adams, Sandip K. Agarwala and Michael D. Culler.
How many employees does Tiburio Therapeutics have?
Tiburio Therapeutics has 7 employees.
Who are Tiburio Therapeutics competitors?
Competitors of Tiburio Therapeutics include LimmaTech Biologics, Biosyntia and Eikon Therapeutics.
Where is Tiburio Therapeutics headquarters?
Tiburio Therapeutics headquarters is located at NE48, 700 Technology Square 2nd Floor, Cambridge.
Where are Tiburio Therapeutics offices?
Tiburio Therapeutics has an office in Cambridge.
How many offices does Tiburio Therapeutics have?
Tiburio Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies